Introduction
Robert Bittman ( For the purpose of this review we have focused on Bittman's contribution to understanding lipid trafficking and the role of sphingolipids (e.g. ceramide, sphingosine and sphingosine 1-phosphate (S1P), ceramide 1-phosphate (C1P)) and phospholipids (e.g. lysophosphatidic acid 2 (LPA), ether glycerol lipids) in cellular communication networks governing cancer biology, inflammation and other diseases. We treat these works in a reflective manner to provide some measure of their impact on the key issues that were facing the field at the time. Indeed, Bittman's research has influenced all the major areas concerning these bioactive lipids and one would hope that his work might ultimately influence the development of therapeutics in the future that will tackle the terrible disease that took his life.
Lipid trafficking
Bittman published extensively on sterol biochemistry. Examples include the assessment of the distribution of cholesterol between the outer and inner halves of the lipid bilayer of mycoplasma cell membranes [1] . He also determined the rates of rapidly exchanging cholesterol and phospholipid pools in sphingomyelin-and phosphatidylcholine-containing membranes [2] . Bittman also investigated how sphingomyelin modulates trans-bilayer distribution of galactosylceramide in phospholipid containing membranes [3] . Using fluorescence quenching assays, he established a role for ceramide in lipid raft organisation and as a determinant of sterol content [4] . Bittman also synthesised BODIPY (borondipyrromethene)-cholesterol, which was then used to visualise sterol trafficking in cells [5] . The egress of BODIPY cholesterol (BC) from late endosomal (LE) organelles is dependent on acid lipase and Niemann-Pick C1 (NPC1) protein [6] . NPC1 was shown to recruit Rab8a to BCcontaining LEs and to thereby enhance the motility and segregation of BC-and CD63-positive organelles from lysosomes. Low density lipoprotein (LDL) increased the number and dynamics of focal adhesions and stimulated cell migration in an acid lipase-, NPC1-and Rab8a-dependent manner. Further advances include the demonstration that N-myc downstreamregulated gene 1 (NDRG1) regulates LDL uptake by LDL receptor [7] . 3 Bittman and colleagues also demonstrated that the Sonic Hedgehog receptor, Patched might contribute to cholesterol efflux from cells, thereby affecting intracellular cholesterol concentration [8] . This activity likely accounts for the inhibition of sonic hedgehog signalling receptor, Smoothened, enrichment at the plasma membrane [8] and which is an important step in activation of the sonic hedgehog signalling pathway. Sonic hedgehog signalling has a critical function in regulating growth and patterning during embryonic development, and also in stem cell maintenance and tissue regeneration in adults. . These studies collectively advanced the lipid trafficking field made possible by ingenious synthesis of highly specific lipid tools.
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Sphingolipid Signalling
In the mid 1990's the concept of the sphingolipid rheostat was proposed, where interconversion of ceramide, sphingosine and S1P by various enzymes was suggested to regulate cellular fate. In this model, shifting the balance toward ceramide induces apoptosis, while predominance of S1P formation promotes cell survival. However, the sphingolipid rheostat exhibits complexity and has recently been re-evaluated [12] , as there is temporal and spatial regulation, where functionality is governed by compartmentalised signalling [13] . A measure of this complexity is evident as conversion of S1P to (E)-2 hexadecenal and phosphoethanolamine can result in formation of phospholipids that have additional defined signalling functions in cells [14] and ceramide can be converted to C1P which has opposing actions to ceramide. Therefore, the regulation of the sphingolipid rheostat in different cellular compartments is likely to provide finer tuning of cell biology than was previously considered.
Bittman made a significant contribution to our understanding of sphingolipid signalling by developing reagents and chemical tools that allowed some of the functions of ceramide, C1P, sphingosine, S1P and hexadecenal to be identified.
Ceramide: stress sensor and responder--In the late 1980s, the hydrolysis of sphingomyelin by sphingomyelinase was demonstrated to constitute a novel signal transduction pathway in mammalian cells. The product, ceramide, can be acylated to sphingosine, which functions to inhibit protein kinase C (PKC) [15] , or phosphorylated to C1P [16] by a calcium-dependent ceramide kinase, the function of which was unknown at the time. Moreover, 1,25-dihydroxyvitamin D3 was shown to activate sphingomyelinase to stimulate differentiation of HL60 cells [17, 18] . Sphingosine had also been demonstrated to promote the phosphorylation of the EGF receptor on Thr 669 in A431 human epidermoid carcinoma cells via a mechanism that was independent of PKC [19] .
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Diacylglycerol and ceramide were shown to have opposing cellular actions. Thus, activation of PKC by diacylglycerol promotes cell survival whereas apoptosis is induced by ceramide [20, 21] . Bittman synthesised a cell-permeable ceramide, N-octanoyl sphingosine (C8-Cer) that was used in collaboration with Kolesnick's group to induce a concentration-and timedependent increase in diacylglycerol levels in cells and which was associated with a reduction in phosphatidic acid levels [22] . C8-Cer was not metabolized to sphingomyelin and promoted PKC translocation from the cytosol to membrane, due to the increase in intracellular diacylglycerol. The mechanism of action of ceramide was resolved by demonstration that it is a competitive (with diacylglycerol) inhibitor of diacylglycerol kinase, the enzyme that catalyses the conversion of diacylglycerol into phosphatidate [22] . Therefore, these studies identified that functional cross-talk between phospholipid-and ceramide-dependent signalling pathways exist in mammalian cells. The significance of these findings contextualised prior studies, which had demonstrated that ceramide promotes apoptotic cell death in the human myeloid leukaemia cell lines HL-60 and U937 [21] and this is suppressed by diacylglycerol [23] .
The role of ceramide in the induction of apoptotic death had become evident from attempts to decipher the signalling mechanisms activated by 1,25-dihydroxyvitamin D3 [17, 18] and which was significantly helped by use of ceramide analogues, such as C2-ceramide [20] . Others demonstrated that ceramide was also able to activate protein phosphatase 2A (PP2A) [24, 25] .
Activation of heterotrimeric PP2A was specific for ceramide because related sphingolipids had no effect. Indeed, dihydro-C2-ceramide, which lacks the trans-double bond in the sphingoid base inhibited PP2A activity. Later studies showed, for instance, that the ceramide-activated protein phosphatase is involved in deactivating the PKB/Akt pathway [26, 27] , down-6 regulating c-Myc [25] and promoting dephosphorylation of retinoblastoma protein to induce growth arrest [28] thereby providing molecular detail to ceramide-dependent signalling and biological responses.
Bittman made contributions in this area with studies investigating the effect of N-octanoylsphingosine (C8-Cer) stereoisomers, N-octanoyl-DL-erythro-dihydrosphingosine (DL-e-DHC8-Cer), and N-octyl-D-erythro-sphingosine (D-e-C8-Ceramine) on apoptosis in U937 cells [29] . D-and L-threo stereoisomers were demonstrated to be more potent than the erythro cytotoxicity than short chain ceramides in BT549, A549, and DU145 cancer cells [31] . The activity was associated with a reduction in cellular glutathione (GSH) level, which had been proposed some time before to be a critical step in neutral sphingomyelinase activation and subsequent ceramide-induced apoptosis [32] . Bittman and colleagues also demonstrated that the C(4)-C(5) trans-double bond has little influence on the ability of apoptosis regulatory proteins, Bax and Bcl-xL, to bind to the ceramide channels [33] . However, the stereochemistry of the head group and access to the amide group of ceramide is essential for Bax, but not BclxL binding. Bcl-xL was shown to also optimally bind long-chain apoptotic ceramides.
Bittman synthesised many FTY720 analogues some of which targeted various key enzymes involved in sphingolipid metabolism such as ceramide synthases and sphingosine kinase.
FTY720 modulates the immune response by preventing egress of T-lymphocytes from lymph nodes [34] . FTY720 (Gilenya TM ) is licenced for oral treatment of relapsing multiple sclerosis and is a pro-drug, which is phosphorylated by sphingosine kinase 2 (SK2). FTY720 phosphate is a functional antagonist of the S1P1 receptor, causing its proteasomal degradation and removal from T-lymphocytes [34] . Since T-lymphocytes use an S1P gradient to egress from lymph nodes, FTY720 is able to prevent this by creating S1P1 null T-lymphocytes that do not respond to the S1P gradient, thereby ablating their action on the central nervous system in multiple sclerosis. However, it is clear that FTY720 can affect other targets in cells. Indeed, Bittman was involved in two studies that demonstrated that FTY720 modulates de novo synthesis of ceramide. In collaboration with Futerman and colleagues, FTY720 was shown to inhibit ceramide synthase activity in a non-competitive manner with acyl-CoA and an uncompetitive manner with sphinganine [35] . The inhibitory effect of FTY720 was dependent on acyl-CoA chain length. Ceramide synthesis was inhibited at high (0.5-5 M) but not low (< 200 nM) sphinganine concentrations in cells. Ceramide, sphingomyelin, and hexosylceramides levels 8 were increased in response to FTY720, possibly a consequence of additional effects on, for instance, sphingosine kinase 1 (SK1). These findings were highly informative in defining the complexity of the mechanism of action of FTY720. FTY720 is known to induce apoptosis of, for instance, cancer cells, and therefore modulation of ceramide levels might underlie, in part, this mechanism of action. In collaboration with Natarajan's group, stable isotope pulse labelling of human pulmonary artery endothelial cells was used to establish that FTY720
modulates de novo ceramide synthesis [36] .
Alpha-galactosylceramide (alphaGalCer) and its isosteric C-glycoside analogue activate Sphingomyelin--Structural activity relationships concerning specificity of sphingomyelinase were studied [38] . Four analogues of sphingomyelin were synthesized by Bittman's laboratory in which the C-3 hydroxyl group was replaced by a hydrogen atom (to produce a deoxysphingomyelin analogue), or with O-methyl, O-ethyl or O-tetrahydropyranyl groups. The deoxy-sphingomyelin analogue failed to compete with a substrate of sphingomyelinase and was not hydrolysed by the enzyme, suggesting that the hydroxyl group is essential for activity.
The size of the alkyl group on the ether moiety was also found to be important. Thus, the 3-
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O-tetrahydropyranyl-sphingomyelin failed to compete with substrate of neutral pH-optimum sphingomyelinase.
Ceramide 1-phosphate--Bittman in collaboration with Gomez-Muñoz and Brindley
demonstrated that C2-and C8-Ceramide-1-phosphates (N-acetylsphingosine-1-phosphate and N-octanoylsphingosine-1-phosphate, respectively) stimulated DNA synthesis and promoted division of fibroblasts [39] . Recent studies by Gomez-Muñoz and Bittman demonstrated that C1P stimulates reactive oxygen species (ROS) formation in primary bone marrow-derived macrophages and that C1P induced ROS formation promotes mitogenesis of macrophages [40] .
This requires activation of NADPH oxidase, which is down-stream of C1P-dependent activation of cytosolic calcium-dependent phospholipase A2 and PKC. Bittman contributed to this study by synthesising BHNB (4-bromo-5-hydroxy-2-nitrobenzhydryl)-C1P (a photolabile caged-C1P analogue), which was critical to the study because it allowed demonstration that C1P elicits these effect via an intracellular action. This was an important advance as it distinguished the actions from those in which C1P can elicit extracellular effects via a putative unidentified cell surface receptor.
Sphingosine--Contributions to this area of research is evident by studies showing that sphingoid
bases synthesised in Bittman's laboratory induced apoptosis in HL-60 and U937 cells via a mechanism that did not involve their acylation to ceramides by ceramide synthases. Thus, Fumonisin B1 (FB1, ceramide synthase inhibitor) failed to abrogate the effects of the sphingoid bases [41] . These sphingoid bases inhibited PKC and potentiated the lethal effects of ceramide, thereby providing evidence that PKC, which is inhibited by sphingoid bases, has a cytoprotective role in leukemic cells. This was followed by studies using phenethylisothiocyanate derivatives of sphinganine and sphingosine (PEITC-Sa and PEITC-So) that were synthesised in Bittman's laboratory [42] . The PEITC-sphingoid base derivatives were shown to exhibit higher cytotoxicity (by PKC inhibition) than their natural counterparts and the clinically tested sphingoid base, safingol. Such studies, highlighted the potential use of synthetic lipids as conventional PKC/novel PKC chemotherapeutic agents.
Bittman also collaborated with Hla's group to identify novel intracellular targets of sphingosine [43] . Using affinity chromatography and proteomics, they identified acidic leucine-rich oncogene, which inactivates PP2A. Bittman synthesised FTY720, which was used to reactivate the PP2A and reduce Jak2(V617F) activity and clonogenic potential [47] . Likewise, FTY720
decreases leukemic allelic burden and splenomegaly and increases Jak2(V617F) leukemic mice survival. The effects of FTY720 require a PP2A interacting protein SET K209. In contrast, FTY720-P, acting as a S1P1 receptor agonist, promotes Jak2-SET-mediated PP2A inhibition.
These findings were important not least in defining the interplay between the S1P signalling pathway, SET2-PP2A and Jak2, but also in identifying novel strategies for eliminating the oncogenic drive in myeloproliferative neoplasm [44] .
Previous studies had demonstrated that sphingosine and FTY720 could disrupt the proliferative signalling of the scaffold and adapter protein 14-3-3 [45] by enabling its protein kinase A (PKA)-catalysed phosphorylation of Ser58 which destabilizes 14-3-3 dimerization. Dimeric 14-3-3 is functional, and the phosphorylation prevents the pro-survival action of 14-3-3 in cells.
In a study published after Bittman's death, Woodcock and colleagues used FTY720 mimetics (quaternary ammonium analogues of FTY720) to stimulate phosphorylation of 14-3-3 at Ser58, which is deep in the interface of the dimer, resulting in mitochondrial-mediated apoptosis.
Bittman laboratory synthesised RB-011 and RB-012, which are poor inhibitors of sphingosine kinase [46] and these were used to disrupt 14-3-3 dimers at low micromolar concentrations and to induce abrogation of Raf-ERK-1/2 and PI3K/Akt signalling in Jurkat cells [47] . RB-011
and RB-012 were also shown to induce apoptosis of human A549 lung cancer cells and RB-012 reduced xenograft growth of these tumours in mice. When mutant phosphorylation deficient 14-3-3 proteins are expressed in cells, they function in a dominant negative manner forming dimers with endogenous 14-3-3 that disrupts ERK-1/2 signalling. The phenotype was recapitulated by RB-012. These compounds were therefore used not only to demonstrate potential therapeutic utility in targeting 14-3-3 as an anti-cancer strategy, but also in delineating novel pathways by which sphingosine can regulate cell death.
Sphingosine 1-phosphate--The first suggestion that S1P might function as a bioactive lipid came from studies showing that sphingosine mobilised calcium from intracellular stores mediated from a product of sphingosine and believed to be S1P [48] . Subsequent studies demonstrated that a number of effects attributed to sphingosine, were mediated by S1P
including the stimulation of DNA synthesis of Swiss3T3 fibroblasts [49] . Others demonstrated that S1P inhibits cell motility and tumour invasiveness [50] . Additional studies characterised the enzymes involved in the metabolism of S1P including sphingosine kinase, S1P lyase and lipid phosphate phosphatases. By the mid 1990's there was compelling evidence that S1P
could also induce pertussis toxin-dependent cell signalling responses, such as ERK-1/2 activation that suggested some of the S1P responses were mediated by specific G proteincoupled receptors (GPCR) [51, 52] ; this was later confirmed by the identification of five S1P-specific GPCR, now termed S1P1-5. In addition, there were several studies that attempted to decipher and distinguish the bioactive functions of ceramide, sphingosine and S1P. Due to the nature of their inter-conversion, delineation of their individual roles was not a trivial exercise.
Several studies lead to the concept of the sphingolipid rheostat. This was deduced from assessment of the effect of ceramides, sphingosine and S1P on phospholipase D activity and mitogenesis in fibroblasts [53] and on ERK-1/2, JNK/SAPK, p70S6K and cAMP signalling in airway smooth muscle cells [54] . Later, S1P was shown to inhibit ceramide-induced cell death, which also blocked ceramide-induced stress activated signalling (JNK/SAPK) in U937 cells and Jurkat cells [55] . These studies provided evidence that elucidated different biological effectors of ceramide, sphingosine and S1P, thereby separating the function of these sphingolipids.
Bittman's interest in S1P started in the mid 1990's when the controversy and debate concerning whether this lipid induced specific cell biological responses was at its height. Spiegel and colleagues had shown that S1P and sphingosylphosphorylcholine (SPC) stimulate DNA binding activity of activator protein-1 (AP-1) in Swiss 3T3 fibroblasts [56] . The collaboration with Bittman demonstrated that the free 2-amino group and the 4E double bond of SPC and S1P were important for AP1 transactivation [57] . A reduction in sphingoid backbone chain length, substitution of the 3-hydroxyl group or saturation of the 4E bond significantly reduced the mitogenic/AP-1 transactivation induced by S1P, but not as significantly for SPC. These early studies highlighted the power of structural-activity relationships in defining functionality to S1P over other sphingolipids, identified S1P as a bona fide bioactive lipid and suggested applications in wound healing and inhibition of metastasis. . The S1P1 receptor bound the benzophenone-containing ligand, while no specific binding was found with the diazirinecontaining ligand. In contrast both ligand bound to plasma carrier proteins (presumably albumin). These studies revealed that different parts of the S1P pharmacophore of S1P interact with its receptor and plasma carrier proteins.
Bittman also explored the activity of FTY720 and FTY720-phosphate in a number of biological systems. For instance, the effect of S1P and FTY720-phosphate on constrictor responses were investigated in bladder smooth muscle (detrusor) in collaboration with Spiegel's group [59] . S1P-induced a phasic and tonic contraction of detrusor muscle that was dependent S1P2. The phasic response required phospholipase C (PLC). FTY720-phosphate, an agonist for all S1P
receptors except S1P2 induced a slow and sustained contraction, suggesting that this contraction phase was dependent on a receptor independent mechanism (possibly calcium Trp channel and/or voltage-operated calcium channels). Detrusor tone is deregulated in overactive bladder 14 syndrome, suggesting that S1P signalling might represent a therapeutic target in this disease.
Bittman and colleagues also achieved the first enantio-selective synthesis of chiral isosteric phosphonate analogues of FTY720 and demonstrated, in collaboration with Tigyi's group, that the (R)-FTY720-vinylphosphonate was a full agonist of S1P1 while the (S) enantiomer was a pan-antagonist of S1P1-5 receptors [60, 61] . and this was associated with an apoptotic effect in prostate and breast cancer cells [62] . Such studies highlighted the complexity of the pharmacological intervention of the S1P signalling pathway.
The biological action of FTY720-phosphate at S1P1 receptors in T-lymphocytes was initially considered to underlie the major effect of this compound in alleviating symptoms of multiple sclerosis. However, there is now a general agreement that FTY720-phosphate can also exert direct effects on the central nervous system. Indeed, there was demonstration of a direct protective effect of FTY720-phosphate on oligodendrocyte progenitors that maintain myelination of neurons in the brain [63] . Treatment of these cells with FTY720 causes activation of ERK-1/2 and Akt, and protection from apoptosis. However, FTY720 also arrested oligodendrocyte differentiation counteracted by neurotrophin-3, which not only enhanced the survival of oligodendrocyte progenitors induced by FTY720 but also stimulated their maturation. These studies raised the possibility that multiple sclerosis therapies with FTY720
should include the use of differentiation-enhancing factors such as neurotrophin-3.
Bittman in collaboration with Garcia, Dudek and Natarajan explored the potential effect of FTY720 analogues on vascular endothelial cell barrier integrity in terms of inflammatory diseases such as acute lung injury. It had been demonstrated that S1P and FTY720 exhibit potent barrier-enhancing activity. Bittman's laboratory synthesised a number of FTY720
analogues that were used in collaboration with Dudek and colleagues to assess effect on endothelial barrier integrity [64] . They demonstrated that the (R)-and (S)-enantiomers of FTY720-phosphonate induced a sustained endothelial cell barrier enhancement that was effective in a lower concentration range and with an earlier onset than either S1P or FTY720.
Indeed, the (S)-FTY720-phosphonate reduced alveolar and vascular permeability in a lipopolysaccharide-stimulated murine model of ALI without induction of lymphopenia. These findings suggest therapeutic utility for FTY720 analogues in reducing pulmonary vascular leakage and inflammation and which might have implication for future treatments of acute lung injury. Indeed, these studies were extended in collaboration with Garcia to demonstrate that radiation-induced lung injury, which is a common toxicity in patients administered thoracic radiotherapy, is reduced by (S)-FTY720-phosphonate, along with decreased radiation-induced gene dysregulation [65] . These results were supported by findings which demonstrated that mice with deletion of SK1 (SK1 -/-) or with reduced expression of certain S1P receptors (S1P1 +/-, S1P2
-/-, and S1P3
-/-) exhibited radiation-induced lung injury susceptibility. (S)-FTY720-phosphonate was also assessed in a bleomycin-induced lung injury model and was shown to reduce lung leak and inflammation, while maintaining S1P1 receptor expression. Indeed, (S)-FTY720-phosphonate does not induce -arrestin recruitment and does not promote S1P1 ubiquitination and proteasomal degradation. This contrasted with FTY720, which did not protect against bleomycin-induced acute lung injury in mice and significantly down-regulated S1P1 receptor expression. The significant advance here was the identification of a compound 16 that promotes barrier integrity but lacks the potential barrier disrupting effect of downregulating S1P1 [66] .
Tigyi and Bittman were also involved in a collaboration to map the binding site of FTY720-phosphate in S1P receptors [67] . To achieve this they exploited the fact that FTY720-phosphate binds to the S1P1 receptor but not the S1P2 receptor. A constructed S1P2 chimera with S1P1 sequence from the N terminus to transmembrane domain 2 was activated by FTY720-phosphate and exhibited an S1P1-like activation. Twelve residues in this inserted domain, distributed in four motifs (a-d), differ between S1P1 and S1P2. Insertion of RPMYY in motif b alone or simultaneous swapping of five other residues in motifs c and d from S1P1
into S1P2 introduced responsiveness to FTY720-phosphate. Thus, the use of FTY720-phosphate enabled insight into specific receptor-ligand interactions.
Studies on sphingosine kinases
The modulation of the sphingolipid rheostat to shift the balance to formation of apoptotic ceramide provides a potential means to abrogate hyper-proliferative diseases such as vascular remodelling in pulmonary hypertension and both solid and haematological cancers.
Sphingosine kinase (SK) is a logical target for therapeutic intervention since inhibition of this enzyme functions to prevent conversion of sphingosine into S1P, with concomitant back conversion of sphingosine into apoptotic ceramide. With this rationale, a collaboration was established between Bittman and the Pyne group to synthesise and test sphingoid base and FTY720 analogue inhibitors of SK1 and SK2. The demonstration that FTY720 inhibits SK1 activity [62] provided a strong rationale for development of FTY720 analogues as SK inhibitors. Moreover, (S)-FTY720 vinylphosphonate was shown to be an allosteric inhibitor of SK1 activity [68, 69] and function to stabilise a conformation of SK1 that enhances auto-inhibition of the catalytic site. In addition, two new FTY720 analogues (a conjugate of sphingosine with a fluorophore and (S)-FTY720 regioisomer) stimulated SK1 activity, suggesting relief of the auto-inhibition of SK1 activity [68] . These studies were extended by demonstration that replacement of the amino group in ( Bittman's laboratory also synthesized inhibitors that were selective for SK1 and SK2. For example, the thiourea adduct of sphinganine (F-02) was selective for SK2 whereas the 1- 4-octylphenethyl)piperidin-4-ol) (RB-005) [46, 75] . Structural activity relationship analysis was performed in which the lipophilic tail, polar head group, and linker region were modified.
Using modelling studies with the recently published crystal structure of SK1, the basis for the key residues targeted by this profiled series was achieved along with identification of determinants that provide a rationale for the development of inhibitors with better selectivity for SK2 over SK1 [75] .
Studies on sphingosine 1-phosphate lyase
Collaboration between Bittman and Saba's group identified temporal and spatial accumulation 
The collaboration between Saba and Bittman also explored whether trans-2-hexadecenal
(produced upon the degradation of S1P by S1P lyase) has signalling functions in cells [81] . 
Lysophosphatidic acid
The biological activity of LPA was first identified in the late 1970's with the demonstration that LPA can induce pressor responses [83], platelet aggregation [84] and neutrophil chemotaxis [85] . In addition, LPA was shown to markedly inhibit synaptic membrane
20
(Na + /K + )-ATPase activity in rat brain suggesting a role in depolarization and/or increase in intracellular calcium concentrations [86] . In the early 1990's LPA was identified as a mitogen that acted through a pertussis sensitive G-protein coupled receptor(s) and p21Ras in fibroblasts [87] [88] [89] . Tigyi et al. [90] demonstrated that LPA bound to serum albumin activated membrane currents in oocytes and induced neurite retraction in PC12 cells. Numerous studies confirmed LPA to be a bioactive lipid and there has been extensive characterization of the receptors that mediate its action. There are multiple species of LPA that account for its pleiotropic actions, including both mitogenic and anti-mitogenic effects in mammalian cellular systems [91] . a naturally occurring analogue of LPA from the slime mould Physarum polycephalum to human blood [93, 94] , alkyl-ether [95, 96] and alkenyl-ether analogues [97] of LPA have also been identified and are weak agonists of LPA-specific GPCR [98, 99] . In contrast, LPA5
exhibits preference for 1-O-alkyl glycerophosphate compared with acyl analogues with the same chain length. LPA binds to two classes of GPCR, namely the EDG family cluster (LPA1- were synthesized and shown to inhibit LPA-stimulated Cl -currents with nM potency in oocytes, thus rendering them as potential antagonists [106, 107] . The D-and L-stereoisomers were equally effective, consistent with the finding that both enantiomers of LPA bind to LPA receptors. Both of these LPA antagonists lacked activity when microinjected into the oocyte and were not effective against acetylcholine, serotonin, and glutamate receptors that had been over-expressed in the oocyte. In this 1996 publication that preceded the molecular cloning of the first LPA GPCR, the differential sensitivity to N-palmitoyl-serine and N-palmitoyl-tyrosine phosphates provided pharmacological evidence for multiple LPA receptor subtypes, which were named low-and high-affinity LPA receptors. However, it took 13 years before Npalmitoyl-serine phosphate was finally re-examined in cells transfected with individual LPA receptors to find that LPA1 was inhibited by this compound with an IC50= 3.45 µM whereas it was a weak agonist of LPA2 (GPR92) [108] . Interestingly, when platelets are pre-incubated with N-palmitoyl-serine phosphate prior to LPA exposure, their response is fully blocked [109, 110] . Platelet activation is mediated by LPA5 [111] . The question arises as to why Npalmitoyl-serine phosphate is inhibitory to this response? One potential explanation lies in the pre-incubation of platelets used in the study where prolonged N-palmitoyl-serine phosphate exposure prior to LPA desensitizes LPA5 in the platelet. Clearly, these acylated amino acid analogues represent a promising scaffold for lead development and deserve more investigation to develop new receptor-specific probes.
22
The pharmacological characterisation of LPA receptors was further advanced by the synthesis and characterisation of the LPA analogues, 1-O-hexadecyl-sn-glycero-3-phosphate (1-C16-GP) and 3-O-hexadecyl-sn-glycero-1-phosphate (3-C16-GP). These were shown to induce calcium mobilisation in RH7777 cells over-expressing either LPA1 or LPA2 or LPA3 indicating a lack of stereo-specificity in their action [112] . The enantiomers also induced Cl -transients in oocytes, which express LPA1 and PSP24 and heterologous desensitisation was evident in NIH3T3 cells (which express LPA1 and LPA2) stimulated with oleoyl-LPA and 1-C16-GP or 3-C16-GP. These findings indicated that these ligands bind to the same LPA receptors.
Finally, both enantiomers were dephosphorylated by the lipid phosphate phosphatase, LPP1.
This study importantly contributed to the notion that LPA binds to LPA receptor in a nonstereospecific manner, while other unnatural analogues, such as N-acyl-serine phosphate and N-acyl-ethanolamine phosphate (which contain a serine and an ethanolamine backbone, respectively, in place of glycerol) bind to LPA receptors in a stereospecific manner. There are also subtle differences in the binding of these ligands to different LPA receptor sub-types. This provided a strong rationale and belief that it is possible to develop sub-type specific antagonists of LPA receptors that might exhibit therapeutic value. Bittman's compound with the glycerol backbone replaced with amino acid analogues had a profound impact on the development of LPA GPCR probes. The realization that the glycerol backbone was not required for the ligand to activate or inhibit the receptors has fuelled the synthesis of fatty alcohol phosphates that completely lack the glycerol moiety yet depend on their hydrocarbon chain-length [113] [114] [115] .
One of these analogues, octadecyl thiophosphate is an effective radioprotective agent that mitigates the acute radiation syndrome in mice and non-human primates via activation of the LPA2 receptor [114, 116, 117] .
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The collaboration with Tigyi also lead to the finding that LPA is formed during mild oxidation of LDL leading to the stimulation of platelet activation and endothelial stress-fibre formation [110] . These effects were blocked by N-palmitoyl-tyrosine phosphate that had been synthesised and characterised in earlier work. The significance of these findings was the identification of LPA in LDL where it is enriched in the lipid core and which is highly atherothrombogenic. The effects on cardiovascular pathology were followed by studies on LPA targets distinct from the LPA GPCR. The basis of these studies was that products formed Information from such studies could conceivably be used to produce LPA analogues with full agonism properties and therefore of high therapeutic value in the treatment of atherosclerosis. synthesis of HL60 cells [123] . A non-hydrolysable analogue of ET16-OCH3-GPC was active, thereby suggesting that biological activity was attributable to ET16-OCH3-GPC rather than a 26 bio-transformed activity [123] . The ether-linked lipids were shown to compete with diacylglycerol/phosphatidylserine for binding sites on PKC, but this was not linked with cytotoxicity [124] . These workers also demonstrated that ET16-OCH3-GPC was not a platelet activating factor receptor modulator [125] . Thus, comparison with platelet activating factor agonists demonstrated opposing rank order potency for platelet aggregation activity versus cytotoxicity against WEHI-3B leukemic cells.
In collaboration with Arthur, the anti-proliferative effect of ET18-OCH3 was demonstrated to involve blockade of Raf-1 association with Ras at the plasma-membrane resulting in ablation of the down-stream activation of the ERK pathway [126, 127] . ET-18-OCH3 was also shown to inhibit the phosphorylation and activation of p70 S6 kinase in MCF-7 Cells [128] .
Subsequently, Bittman synthesised enantiomeric unsaturated phosphonocholine analogues of ET-16-OCH3 which displayed differential cytotoxicity towards two neuroblastoma cell lines, SK-N-SH and SK-N-MC [129] . This was the first report of enanatioselectivity of AELs on antiproliferative activity and cytotoxicity. The differential cytotoxic effects of the enantiomers were demonstrated to be due to the differential activation of the JNK signalling pathway in the cells [129] .
Bittman with Arthur reported the synthesis of a GAEL, 1-O-hexadecyl-2-O-methyl-3-O-(2'-amino-2'-deoxy-beta-D-glucopyranosyl)-sn-glycerol (Gln) that had comparable or better cytotoxic effects against human epithelial cancer cell lines than ET-18-OCH3 [130] . They demonstrated the mechanism by which glycosylated anti-tumour ether lipids (GAELs) exhibit anti-cancer activity. Gln activates autophagy but does not kill cells by this mechanism or through apoptosis [131] . Later studies demonstrated that Gln neutralises lysosomal pH, increases autolysosome formation and promotes lysosomal membrane permeabilization with 27 the release of hydrolases into the cytoplasm, which then promote cell death [132] . phosphatidylinositol. C4-PI was shown to inhibit PI-phospholipase C-beta (PLC-) while activating PI-PLC and PI-PLC at low concentrations and inhibiting these enzymes at higher concentrations. C4-PI had little effect on PI4-kinase activity and blocked the proliferation of MCF-7 and MDA-MB-468 cell lines [135] .
Synopsis
In the present review we compiled a partial account of the contributions made by Robert
Bittman to select areas of lipid research. His legacy will live on not only in over 340
publications he authored but also in the concepts that evolved from research enabled by the compounds he made available to lipid researchers. The compounds he synthesized not only had a profound impact on the pursuit of the biological function of several important lipid mediators but also accelerated research toward their therapeutic exploitation.
